201 related articles for article (PubMed ID: 28445579)
21. Complete remission of extensive cutaneous metastatic melanoma on the scalp under topical mono-immunotherapy with diphenylcyclopropenone.
Hinz T; Ehler LK; Bieber T; Schmid-Wendtner MH
Eur J Dermatol; 2013; 23(4):532-3. PubMed ID: 24002471
[No Abstract] [Full Text] [Related]
22. Pembrolizumab (Keytruda°) and metastatic or inoperable melanoma.
Prescrire Int; 2017 May; 26(182):118-119. PubMed ID: 30730667
[No Abstract] [Full Text] [Related]
23. Successful Anti-PD-1 Antibody Treatment in a Metastatic Melanoma Patient With Known Severe Autoimmune Disease.
Maul LV; Weichenthal M; Kähler KC; Hauschild A
J Immunother; 2016 May; 39(4):188-90. PubMed ID: 27023060
[TBL] [Abstract][Full Text] [Related]
24. Complete response to immunotherapy in a nonagenarian patient with metastatic melanoma.
Foo T; Tapia Rico G; Brown MP
BMJ Case Rep; 2020 Jul; 13(7):. PubMed ID: 32699060
[TBL] [Abstract][Full Text] [Related]
25. [Treating metastatic melanoma: Risk management].
Lebbe C; Robert C
Ann Dermatol Venereol; 2017 Jan; 144(1):3-5. PubMed ID: 28063593
[No Abstract] [Full Text] [Related]
26. Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.
Andtbacka RH; Agarwala SS; Ollila DW; Hallmeyer S; Milhem M; Amatruda T; Nemunaitis JJ; Harrington KJ; Chen L; Shilkrut M; Ross M; Kaufman HL
Head Neck; 2016 Dec; 38(12):1752-1758. PubMed ID: 27407058
[TBL] [Abstract][Full Text] [Related]
27. Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?
Diem S; Keller F; Rüesch R; Maillard SA; Speiser DE; Dummer R; Siano M; Urner-Bloch U; Goldinger SM; Flatz L
J Immunother; 2016; 39(9):379-382. PubMed ID: 27662340
[TBL] [Abstract][Full Text] [Related]
28. Distinguishing melanophages from tumor in melanoma patients treated with talimogene laherparepvec.
Audrey-Bayan C; Trager MH; Gartrell-Corrado RD; Rizk EM; Pradhan J; Silverman AM; Lopez A; Marks DK; Niedt G; Geskin LJ; Saenger YM
Melanoma Res; 2020 Aug; 30(4):410-415. PubMed ID: 32379409
[TBL] [Abstract][Full Text] [Related]
29. Vitiligo-like lesions located over In-transit metastases of malignant melanoma as a clinical marker of complete response to pembrolizumab.
Gracia-Cazaña T; Padgett E; Hernández-García A; Sánchez-Salas MP
Dermatol Online J; 2019 Dec; 25(12):. PubMed ID: 32045170
[TBL] [Abstract][Full Text] [Related]
30. Pembrolizumab for Recurrent Conjunctival Melanoma.
Kini A; Fu R; Compton C; Miller DM; Ramasubramanian A
JAMA Ophthalmol; 2017 Aug; 135(8):891-892. PubMed ID: 28715523
[No Abstract] [Full Text] [Related]
31. Squamous cell carcinoma associated with chronic graft versus host disease-like/lichen planus-like lesion of the oral cavity in a patient managed for metastatic melanoma with a PD-1 inhibitor pembrolizumab.
Owosho AA; Randazzo J; Rosen EB; Estilo CL; Huryn JM; Chi P; Yom SK
Oral Oncol; 2016 Dec; 63():e1-e3. PubMed ID: 27743938
[No Abstract] [Full Text] [Related]
32. Novel therapies for unresectable and metastatic melanoma.
Karimkhani C; Reddy BY; Dellavalle RP; Sundararajan S
BMJ; 2017 Nov; 359():j5174. PubMed ID: 29191943
[No Abstract] [Full Text] [Related]
33. Intralesional and systemic immunotherapy for metastatic melanoma.
Luu C; Khushalani NI; Zager JS
Expert Opin Biol Ther; 2016 Dec; 16(12):1491-1499. PubMed ID: 27602429
[TBL] [Abstract][Full Text] [Related]
34. Pembrolizumab-Induced Extensive Panniculitis and Nevus Regression: Two Novel Cutaneous Manifestations of the Post-immunotherapy Granulomatous Reactions Spectrum.
Burillo-Martinez S; Morales-Raya C; Prieto-Barrios M; Rodriguez-Peralto JL; Ortiz-Romero PL
JAMA Dermatol; 2017 Jul; 153(7):721-722. PubMed ID: 28467548
[No Abstract] [Full Text] [Related]
35. Inflammatory Myopathy and Axonal Neuropathy in a Patient With Melanoma Following Pembrolizumab Treatment.
Diamantopoulos PT; Tsatsou K; Benopoulou O; Anastasopoulou A; Gogas H
J Immunother; 2017; 40(6):221-223. PubMed ID: 28498142
[TBL] [Abstract][Full Text] [Related]
36. Follow-up on Programmed Cell Death 1 Inhibitor for Cutaneous Squamous Cell Carcinoma.
Tran DC; Colevas AD; Chang AL
JAMA Dermatol; 2017 Jan; 153(1):92-94. PubMed ID: 27784038
[No Abstract] [Full Text] [Related]
37. Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience.
Louie RJ; Perez MC; Jajja MR; Sun J; Collichio F; Delman KA; Lowe M; Sarnaik AA; Zager JS; Ollila DW
J Am Coll Surg; 2019 Apr; 228(4):644-649. PubMed ID: 30690076
[TBL] [Abstract][Full Text] [Related]
38. Killing two birds with one stone: response to pembrolizumab in a patient with metastatic melanoma and B-cell chronic lymphocytic leukaemia.
Arenbergerova M; Fialova A; Arenberger P; Gkalpakiotis S; Jirasek T; Srp A; Novotna A; Frankova H
J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):e72-e74. PubMed ID: 28833722
[No Abstract] [Full Text] [Related]
39. Locally advanced head and neck squamous cell carcinoma and melanoma simultaneously treated with pembrolizumab: an unusual situation.
Mora-Fernández V; Boada A; Manzano JL; Jaka A; Ferrándiz C
Eur J Dermatol; 2020 Dec; 30(6):743-744. PubMed ID: 33237032
[No Abstract] [Full Text] [Related]
40. [White hair turns brown].
Füessl HS
MMW Fortschr Med; 2013 Nov; 155(20):34. PubMed ID: 24482928
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
